References
- Sullivan DJ, Moran GP, Coleman DC. Candida dublin-iensis: ten years on. FEMS Microbiol Lett 2005; 253: 9–17
- Pinjon E, Moran GP,Coleman DC, Sullivan DJ. Azole sus-ceptibility and resistance in Candida dubliniensis. Biochem Soc Trans 2005; 33: 1210–1214
- Mubareka S, Vinh DC, Sanche SE. Candida dubliniensis bloodstream infection: a fatal case in a lung transplant recipient. Transplant Infect Dis, 2005; 7: 146–149
- Chan-Tack KM. Fatal Candida dubliniensis septicaemia in patients with AIDS. Clin Infect Dis 2005; 40: 1208–1209
- McMullan R, Hu J, Moore JE et al Candida dubliniensis bloodstream infection in patients with gynaecological malignan-cies. Eur J Clin Microbiol Infect Dis 2002; 21: 635–636
- Mels JFGM, Ruhnke M, de Pauw BE et al. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 1999; 5: 150–153
- Tan AL, Wang FCY, Chiu YW. Candida dubliniensis In-fection, Singapore. Emerg Infect Dis 2002 ; 8: 445–446
- Jabra-Rizk MA, Johnson JK, Forrest G, Mankes K, Meiller TF, Venezia RA. Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin Infect Dis 2005; 41: 1064–1067
- Ramage G, Walle KV, Wickes BL, Lopez-Ribot J. Biofilm formation by Candida dubliniensis. J Clin Microbiol, 2001; 39: 3234–3240
- Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, et al. Comparison of the epidemiology, drug resist-ance mechanisms and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004; 4: 369–376
- Sagado-Parreno FJ, Alcoba-Florez J, Arias A, Moragues MD, Quindos G, Ponton J, et al. In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre Yeast One, disk diffusion and Etest methods. Microb Drug Resist 2006; 12: 246–251
- Gerzenshtein L, Pathel SM, Scarsi KK, Postelnick MJ, Fla-herty JP. Breakthrough Candida infection in patients receiving Voriconazole. Ann Pharmacother 2005; 39: 1342–1345
- Shuford JA, Rouse MS, Piper KE, et al. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter in-fection model. J Infect Dis. 2006; 194: 710–713.
- Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options . Curr Opin Inves-tig. Drugs 2004; 5: 186–197
- Tortorano AM, Prigitano A, Biraghi E, Viviani MA; FIMUA-ECMM Candidaemia Study Group. The European Con-federation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother 2005; 56: 777–779